Publicaciones (20) Publicaciones de ITXASO BUESA SOBERA

2022

  1. Short-term improvements in the body schema can modulate pain perception in fibromyalgia syndrome

    Clinical and Experimental Rheumatology, Vol. 40, Núm. 6, pp. 1127-1135

2018

  1. Diseño e implementación de un sistema de autoaprendizaje de modelos anatómicos mediante videos didácticos

    Teknologia berriak eta gaur egungo Hezkuntza joerak (Servicio Editorial = Argitalpen Zerbitzua), pp. 6-14

2017

  1. Characterization of functional μ opioid receptor turnover in rat locus coeruleus: an electrophysiological and immunocytochemical study

    British Journal of Pharmacology, Vol. 174, Núm. 16, pp. 2758-2772

2016

  1. Dopamine D1-like receptors regulate constitutive, μ-opioid receptor-mediated repression of use-dependent synaptic plasticity in dorsal horn neurons: More harm than good?

    Journal of Neuroscience, Vol. 36, Núm. 20, pp. 5661-5673

  2. Regulation of nociceptive plasticity threshold and DARPP-32 phosphorylation in spinal dorsal horn neurons by convergent dopamine and glutamate inputs

    PLoS ONE, Vol. 11, Núm. 9

  3. Spinal D1-like dopamine receptors modulate NMDA receptor-induced hyperexcitability and NR1 subunit phosphorylation at serine 889

    Neuroscience Letters, Vol. 618, pp. 152-158

2015

  1. Plasticity of α2-adrenergic spinal antinociception following nerve injury: Selective, bidirectional interaction with the delta opioid receptor

    Brain Research, Vol. 1594, pp. 190-203

2014

  1. Coupling of serotonergic input to NMDA receptor-phosphorylation following peripheral nerve injury via rapid, synaptic up-regulation of ND2

    Experimental Neurology, Vol. 255, pp. 86-95

  2. Synaptic upregulation and superadditive interaction of dopamine D2- and μ-opioid receptors after peripheral nerve injury

    Pain, Vol. 155, Núm. 12, pp. 2526-2533

2013

  1. Transient, 5-HT2B receptor-mediated facilitation in neuropathic pain: Up-regulation of PKCγ and engagement of the NMDA receptor in dorsal horn neurons

    Pain, Vol. 154, Núm. 9, pp. 1865-1877

2012

  1. Is psychological distress intrinsic to fibromyalgia syndrome? Cross-sectional analysis in two clinical presentations

    Rheumatology International, Vol. 32, Núm. 11, pp. 3463-3469

  2. Selective impairment of spinal mu-opioid receptor mechanism by plasticity of serotonergic facilitation mediated by 5-HT2A and 5-HT2B receptors

    Pain, Vol. 153, Núm. 7, pp. 1418-1425

  3. Synergy abilities of spinal opioids receptors: A novel approach for polyanalgesic therapy?

    Opioids: Pharmacology, Clinical Uses and Adverse Effects (Nova Science Publishers, Inc.), pp. 59-74

  4. Time-dependent cross talk between spinal serotonin 5-HT2A receptor and mGluR1 subserves spinal hyperexcitability and neuropathic pain after nerve injury

    Journal of Neuroscience, Vol. 32, Núm. 39, pp. 13568-13581

2010

  1. Subtype-specific changes in 5-HT receptor-mediated modulation of C fibre-evoked spinal field potentials are triggered by peripheral nerve injury

    Neuroscience, Vol. 168, Núm. 3, pp. 831-841

2009

  1. Valoración de factores sociales y clínicos en el síndrome de fibromialgia

    Revista de la Sociedad Espanola del Dolor, Vol. 16, Núm. 6, pp. 323-329

2008

  1. Depression of C fibre-evoked spinal field potentials by the spinal δ opioid receptor is enhanced in the spinal nerve ligation model of neuropathic pain: Involvement of the μ-subtype

    Neuropharmacology, Vol. 55, Núm. 8, pp. 1376-1382

  2. Morphine-induced depression of spinal excitation is not altered following acute disruption of GABAA or GABAB receptor activity

    European Journal of Pain, Vol. 12, Núm. 6, pp. 677-685

  3. Non-linear morphine-induced depression of spinal excitation following long-term potentiation of C fibre-evoked spinal field potentials

    European Journal of Pain, Vol. 12, Núm. 6, pp. 814-817

2006

  1. Disinhibition of spinal responses to primary afferent input by antagonism at GABA receptors in urethane-anaesthetised rats is dependent on NMDA and metabotropic glutamate receptors

    Neuropharmacology, Vol. 50, Núm. 5, pp. 585-594